Effect of the "Sitting Out of Bed in an Arm-chair Position" in ICU on Functional Recovery Among Ventilated Patients

NCT ID: NCT06973746

Last Updated: 2025-12-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

150 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-07-04

Study Completion Date

2028-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Chair positioning is one of a series of early mobilization techniques. At present, this technique, which involves moving a patient out of the resuscitation bed, can be performed passively or actively. It does not constitute a rehabilitative act as such, but it is considered in common paradigms as a technique to improve "the patient's breathing and strength".

However, recommendations issued in 2013 by the Society of intensive care physiotherapy and the society "Société de réanimation de langue française (SRLF)", reveal that this chair position cannot be recommended with a high grade.

The aim of the investigators is therefore to break down this early mobilization process in intensive care, to find out whether the armchair is an indispensable tool for improving functional and muscular processes.

The research hypothesis is therefore as follows:

"Early armchairing of the resuscitation patient, improves functional recovery compared to a conservative positioning strategy (sitting in bed)."

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

ICU Acquired Weakness

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

mechanical ventilation ICU Acquired Weakness Arm Chair Sitting Early mobility

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

sitting out of bed in an arm-chair position

Group Type EXPERIMENTAL

sitting out of bed in an arm-chair position

Intervention Type OTHER

Once the patient has been awake with a RASS score between -1 and +1 for more than 12 hours, he or she must be placed in a chair (by any means) every day for a minimum of 30 minutes until "discharge" from intensive care (or until D28, depending on which comes first), unless there are transient contraindications. If the patient is unable to signal his or her wish to stop the chair session, the criteria for intolerance will be sought and the patient placed in the chair, but in all cases the chair session will not exceed 4 hours.

No chair position

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

sitting out of bed in an arm-chair position

Once the patient has been awake with a RASS score between -1 and +1 for more than 12 hours, he or she must be placed in a chair (by any means) every day for a minimum of 30 minutes until "discharge" from intensive care (or until D28, depending on which comes first), unless there are transient contraindications. If the patient is unable to signal his or her wish to stop the chair session, the criteria for intolerance will be sought and the patient placed in the chair, but in all cases the chair session will not exceed 4 hours.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patient \> 18 years old
2. Patient on invasive mechanical ventilation for more than 24 hours
3. Patient in recovery phase with a RASS score greater than "-3" for more than 12 hours
4. Stay expected to last 48 hours
5. Patient has never been placed in a chair during this hospitalization in intensive care.
6. Fragility score \< 6, during the month preceding admission to intensive care
7. Patient (or support person/relative if patient is unable to participate) who has agreed to take part in the study.

Exclusion Criteria

1. Patient with an absolute and non-resolving contraindication to chair positioning

1. Fracture or orthopedic disorder contraindicating mobilization out of bed
2. Obesity with body mass index greater than 45 kg/cm2
3. Sacral eschar stage greater than 2
2. Patient using a wheelchair for mobility (i.e. paraplegic patient or patient with progressive neurological pathology).
3. Patient treated with veno-venous or veno-arterial ECMO at the time of screening.
4. Moribund patient
5. Encephalic death
6. Acute polyradiculoneuritis (Guillain-Barré syndrome)
7. Myasthenia
8. Patient treated by continuous hemodialysis or hemofiltration for more than 72 hours following the onset of awakening.
9. Complete transmetatarsal or higher amputation of one or both lower limbs.
10. Protected person (under guardianship or curatorship)
11. Person under court protection
12. Person not affiliated to a social security scheme
13. Pregnant or breast-feeding woman
14. Patient already included in the study
15. Patient taking part in an interventional clinical study, the aim of which is to show an improvement in functional level on discharge from the intensive care unit or which focuses on the theme of early rehabilitation in the intensive care unit.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Centre Hospitalier Régional d'Orléans

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Guillaume FOSSAT

Role: PRINCIPAL_INVESTIGATOR

CHU Orléans

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Centre Hospitalier Universitaire d'Orléans

Orléans, Centre-Val de Loire, France

Site Status RECRUITING

Hopital Nord Franche Comte

Belfort, , France

Site Status RECRUITING

CHU Clermont Ferrand

Clermont-Ferrand, , France

Site Status RECRUITING

CH de DAX

Dax, , France

Site Status NOT_YET_RECRUITING

CHU de DIJON

Dijon, , France

Site Status RECRUITING

CH Chartres

Le Coudray, , France

Site Status RECRUITING

Ch Du Mans

Le Mans, , France

Site Status RECRUITING

CHI Mont de Marsan

Mont-de-Marsan, , France

Site Status RECRUITING

CH de Saint-Lô

Saint-Lô, , France

Site Status NOT_YET_RECRUITING

Hopital Foch

Suresnes, , France

Site Status NOT_YET_RECRUITING

CHRU de TOURS

Tours, , France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Guillaume FOSSAT

Role: CONTACT

Phone: +33238651318

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Guillaume FOSSAT

Role: primary

Valerie CHAUVIN

Role: primary

Angelina BARRAGE

Role: primary

Adrien AUVET, Dr

Role: primary

Jose Arturo PINEDA, Pr

Role: primary

Florence SMIS

Role: primary

Maie-Hélène LEROYER

Role: primary

Arnaud DELAHAYE, Dr

Role: primary

Edouard GAUQUELIN

Role: primary

Matthieu REFFIENNA

Role: primary

Baptiste DARDAINE

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CHUO-2024-17

Identifier Type: -

Identifier Source: org_study_id